Future directions in the development of pemetrexed

Area of Science:

• Oncology
• Pharmacology
• Medical Chemistry

Background:

• Pemetrexed is a novel antifolate drug.
• It inhibits multiple folate-dependent enzymes, including thymidylate synthase.
• This mechanism offers potential advantages over existing antifolates and fluoropyrimidines.

Purpose of the Study:

• To evaluate the efficacy and safety of Pemetrexed in solid tumors.
• To determine optimal dosing and scheduling.
• To assess combination therapies with other chemotherapeutic agents.

Main Methods:

• Phase I studies established a dosing schedule of intravenous Pemetrexed every 3 weeks.
• Phase II studies assessed Pemetrexed's activity across various solid tumors.
• Combination studies included Pemetrexed with cisplatin, carboplatin, and gemcitabine.

Main Results:

• Pemetrexed demonstrated significant activity in non-small cell lung, colorectal, and pancreatic cancers.
• Combination regimens with platinum agents and gemcitabine showed encouraging results in lung cancer and mesothelioma.
• Life-threatening toxicities were mitigated by co-administration of folic acid and vitamin B12, addressing functional folate deficiency.

Conclusions:

• Pemetrexed is an effective antifolate agent with a broad spectrum of activity in solid tumors.
• The identified toxicity management strategy enhances its therapeutic potential.
• Pemetrexed represents a promising new therapeutic option in solid tumor oncology.